A very recent study from Kolijn et al. 14 described an antioxidant effect of empagliflozin, in humans with heart failure with preserved ejection fraction as well as in ZDF obese rats, evaluated by lipid peroxidation levels, which was accompanied by improved NO-sGC-PKG signalling. Here, SGCB is linked to heart failure.